Dennis 马里兰州Slamon, PhD
Institutional Affiliation
教育
奖学金
实习
度
住院医生实习期
Board Certifications
联系信息
电子邮件
电话
临床利益
的科学兴趣
在过去的12年里. 丹尼斯Slamon and his colleagues conducted clinical and laboratory research that led to the development of the breast cancer drug Herceptin. The drug targets a specific genetic alteration found in about 30 percent of breast cancer patients. 1998年，美国政府宣布.S. Food and Drug Administration approved the use of the Herceptin monoclonal antibody for treatment of advanced breast cancer. Slamon's research proved a relationship between the gene HER-2/neu, which encodes a tyrosine kinase, and a particularly aggressive form of breast cancer. He continues to place research as one of his top priorities, and is currently investigating the effectiveness of Herceptin in newly diagnosed breast cancer patients. Slamon is also working to develop new treatments for women with breast and ovarian cancers.
Highlighted Publications
布里顿CD, Kabbinavar F, Randolph Hecht J, Bello CL, Li J, Baum C, Slamon D, Hecht JR. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2007.
Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. 达沙替尼, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007.
Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. 巨蟹座. 2007; 7(4): 309-15.
Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya KS, Slamon DJ, Mackey JR. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev. 2007; 16(5): 1026-31.
明斯特PN, 布里顿CD, Mita米, Gelmon K, 明顿SE, 铸工年代, Slamon DJ, 郭F, Letrent SP, 丹尼斯·L, Tolcher啊. First study of the safety, 耐受性, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. 临床癌症研究中心. 2007; 13(4): 1238-45.
